EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY-NC 4.0

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Katie Lyman, JinCheol Choi, Didier Jutras-Aswad, Bernard Le Foll, Sukhpreet Klaire iD, M Eugenia Socias

Drug and Alcohol Review · 2026-07 · 45 (5)

DOI: 10.1111/dar.70190 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Drug and Alcohol Review, online erschienen am 18.06.2026. Verfasst von Katie Lyman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Methadone, Buprenorphine, Naloxone Drug Combination, Opioid-Related Disorders, Pain. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Research in Substance Matters, Health Canada's Substance Use and Addictions Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD). This study estimated the impact of type of OAT on pain among individuals with non‐heroin OUD.

Methods

Using data from OPTIMA, a Canadian, randomised, 24‐week clinical trial comparing buprenorphine/naloxone (via take‐home doses) to methadone (via daily witnessed ingestion) for the treatment of non‐heroin OUD, we evaluated the impact of type of OAT on pain outcomes (measured by the Brief Pain Inventory) among participants with major pain at baseline.

Results

Mean pain severity scores significantly decreased in both arms over 24 weeks (methadone 4.89–2.16, buprenorphine/naloxone 4.94–1.08). There was a time by arm interaction, suggesting better performance of buprenorphine/naloxone up to week 9, and methadone afterwards. Mean pain‐related function scores also significantly decreased over time (methadone 5.31–2.70, buprenorphine/naloxone 5.56–3.37), with no significant differences in overall scores between arms ( p = 0.675). Methadone was associated with higher odds of achieving both pain severity and pain‐related function response at week 24 (30% reduction in pain scores from baseline). Discussion and Conclusions Among people with non‐heroin OUD initiating OAT, both methadone and buprenorphine/naloxone were associated with improvements in pain outcomes. However, methadone was associated with a higher likelihood of achieving pain severity and functional treatment response at week 24. These findings suggest the need to consider the type of OAT in the shared‐decision making process for people with non‐heroin OUD and comorbid pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneBuprenorphine, Naloxone Drug CombinationOpioid-Related DisordersPainAnalgesics, OpioidHumansCanadaFemaleAdultMaleTreatment OutcomeOpiate Substitution TreatmentMiddle AgedPain Measurement

Stichwörter der Autor:innen

buprenorphinemethadoneopioid agonist treatmentopioid use disorderpain

Substanzen

MethadoneBuprenorphine, Naloxone Drug CombinationAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Medicine, University of British Columbia, Vancouver, Canada.
  • British Columbia Centre on Substance Use, Vancouver, Canada.
  • Research Centre, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.
  • Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
  • Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada.

ORCID-Profile: Sukhpreet Klaire

Förderung

  • CIHR
  • Canadian Research in Substance Matters
  • Health Canada's Substance Use and Addictions Program
  • Canadian Institutes of Health Research

Zitieren

APA

Lyman, K., Choi, J., Jutras-Aswad, D., Le Foll, B., Klaire, S., & Socias, M. E. (2026). Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial. Drug and Alcohol Review, 45(5). https://doi.org/10.1111/dar.70190

Vancouver

Lyman K, Choi J, Jutras-Aswad D, Le Foll B, Klaire S, Socias ME. Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial. Drug and Alcohol Review. 2026;45(5). doi:10.1111/dar.70190

BibTeX
@article{Lyman2026,
  author = {Lyman, Katie and Choi, JinCheol and Jutras-Aswad, Didier and Le Foll, Bernard and Klaire, Sukhpreet and Socias, M Eugenia},
  title = {Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial},
  journal = {Drug and Alcohol Review},
  year = {2026},
  volume = {45},
  number = {5},
  doi = {10.1111/dar.70190}
}
Kostenlos starten →